Weight loss drugs improve heart health regardless of amount of weight lost: study
As the popularity of GLP-1 receptor agonists for weight loss continues to grow, researchers continue to examine how these medications might impact other areas of a person’s health. In 2023, published research findings reported that semaglutide could potentially reduce a person’s risk for heart attack, stroke, and major cardiac events by 20%. Building off this research, a new study offers further evidence of semaglutide and lowered major cardiac event risk, regardless of how much weight a person loses while taking the GLP-1 medication.